Up in smoke: the SRI case for marijuana (Citywire Selector)


Marijuana’s hip image is changing into something altogether more pedestrian thanks to its rising profile in medicine. Extracts of cannabis have been recommended for anorexia, pain relief and epilepsy. As the substance swaps the streets for the pharmacy shelves, some investors spy an opportunity.

In 2016 the medical marijuana market posted revenues of $6.3 billion, up from 30% the previous year. In 2017, two marijuana-focused ETFs were launched comprising stocks such as British firm GW Pharmaceuticals and Canada-based medical cannabis group Canopy Growth Corporation.

- Promotion -



Partner content

As climate change rises up the political agenda throughout the West and beyond, shareholders have an important role to play in limiting global fossil fuel consumption by pressuring oil companies to amend their strategies, argues Sora Utzinger.

NordSIP Insights

Most read this week

Renewable Diesel – A Eureka moment

This article is part of NordSIP Insights - ESG Integration Case Book 2020. Read or Download the entire publication here. Talking to us from New...